Anesthesiology and Clinical Science Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Anesthesiology and Clinical Science Research (2025) Volume 9, Issue 2

Anesthesia & pain: Safety, innovation, outcomes

Marta González*

Department of Pharmacology, University of Barcelona, Barcelona, Spain

*Corresponding Author:
Marta González
Department of Pharmacology
University of Barcelona, Barcelona, Spain.
E-mail: m.gonzalez@ub.es

Received : 02-Jun-2025, Manuscript No. aaacsr-217; Editor assigned : 04-Jun-2025, PreQC No. aaacsr-217(PQ); Reviewed : 24-Jun-2025, QC No aaacsr-217; Revised : 03-Jul-2025, Manuscript No. aaacsr-217(R); Published : 14-Jul-2025 , DOI : 10.35841/aaacsr-9.2.217

Citation: González M. Anesthesia & pain: Safety, innovation, outcomes. aaacsr. 2025;09(02):217.

Visit for more related articles at Anesthesiology and Clinical Science Research

Introduction

Understanding intravenous anesthetics is crucial in modern medical practice. For instance, propofol, a frequently used agent, is extensively reviewed. This work details its pharmacokinetics and pharmacodynamics, highlighting its rapid onset and short duration. These properties make it versatile, but clinicians must understand its dose-dependent effects on organ systems for safe administration[1].

Perioperative pain management, especially with opioids, plays a pivotal role in surgical settings. An article explores recent advancements in opioid pharmacology for surgical pain control. It discusses various opioid options, their mechanisms, and how professionals optimize use while minimizing side effects, including opioid-sparing strategies and multimodal analgesia approaches[2].

The full understanding of how inhaled anesthetics work remains an active research area. One review offers a comprehensive look at theories and targets, from GABA-A receptors to potassium channels. It makes clear that general anesthesia involves complex molecular interactions, not a single pathway, but a symphony of effects across the central nervous system[3].

Neuromuscular blocking agents are indispensable in surgery, but proper reversal is critical. This paper details their pharmacology, covering depolarizing and non-depolarizing types, and crucially, drugs like sugammadex and neostigmine used for reversal. Understanding their action and reversal mechanisms is fundamental to preventing residual paralysis post-surgery[4].

While local anesthetics are generally safe, systemic toxicity is a significant concern. One article gives a solid overview of Local Anesthetic Systemic Toxicity (LAST), its clinical pharmacology, diagnostic signs, and current management strategies. It emphasizes the critical importance of understanding these drugs’ systemic effects and patient risk factors for safe regional anesthesia[5].

Dexmedetomidine, an alpha-2 agonist, is an important agent in anesthesia. A comprehensive review explores its multifaceted uses, from sedation and analgesia to its opioid-sparing effects. The authors examine its pharmacological profile and evidence supporting its applications, noting its neuroprotective and organ-protective potential, making it interesting for complex cases[6].

Perioperative pharmacogenomics suggests the future of anesthesia might be linked to individual genes. An insightful article reviews how genetic variations affect patient response to anesthetic and analgesic drugs, paving the way for personalized medicine. Understanding these genetic factors could help predict efficacy and adverse effects, moving towards individualized drug regimens[7].

Ketamine is far more than just an anesthetic; this review highlights its unique pharmacology. It covers its dissociative anesthetic properties, analgesic effects, and emerging role in treating depression. The authors also discuss side effects, emphasizing the importance of understanding its complex profile for safe and effective clinical application across various settings[8].

A big worry in anesthesia is its impact on brain function, particularly cognition. This article tackles anesthetic-induced cognitive dysfunction, summarizing current understanding of its causes and involved pathways. The authors discuss both short-term and long-term impacts, pushing for more research into prevention and better identification of at-risk patients, a critical area for patient safety[9].

A new player in anesthetics is remimazolam. This article introduces this ultrashort-acting benzodiazepine, detailing its unique pharmacology, especially its metabolism by tissue esterases, which gives it a predictable and rapid offset. This is exciting as it could offer a more titratable and safer option for anesthesia induction, maintenance, and procedural sedation, compared to older drugs[10].

 

Conclusion

The pharmacology of anesthetic and pain management agents is a dynamic field, crucial for patient safety and effective care. Propofol and inhaled anesthetics are foundational, with ongoing research elucidating their complex mechanisms and pharmacokinetic profiles for safer administration. New agents like remimazolam, an ultrashort-acting benzodiazepine, offer advancements with predictable offsets, enhancing titratability. Opioids remain vital for pain, with clinicians refining strategies like multimodal analgesia and opioid-sparing techniques to minimize side effects. Other critical drugs include neuromuscular blocking agents, necessitating precise reversal strategies to prevent residual paralysis, and local anesthetics, where understanding systemic toxicity is paramount for safe regional applications. Dexmedetomidine expands options with its sedative, analgesic, and organ-protective properties. Beyond specific drugs, broader themes like perioperative pharmacogenomics promise personalized medicine by tailoring drug regimens based on genetic variations. Furthermore, addressing anesthetic-induced cognitive dysfunction is a growing concern, pushing for better understanding of its causes and prevention to improve long-term patient outcomes. These areas highlight a collective effort to optimize anesthetic practice through informed pharmacology, patient-specific approaches, and continuous safety improvements.

References

  1. Mengqi L, Jin L, Yang L. Pharmacokinetics and Pharmacodynamics of Propofol: A Comprehensive Review. Drug Des Devel Ther. 2021;15:3003-3024.

    2. Indexed at, Google Scholar, Crossref

  2. Ruchi G, Prachi JS, Madhvi S. Advances in opioid pharmacology for perioperative pain management. J Anaesthesiol Clin Pharmacol. 2023;39(1):31-36.

    3. Indexed at, Google Scholar, Crossref

  3. Ming Z, Xiaojuan H, Hongbing X. Mechanisms of action of inhaled anesthetics: a comprehensive review. Chin Med J (Engl). 2022;135(1):3-10.

    4. Indexed at, Google Scholar, Crossref

  4. Joseph MA, Katherine CA, Alexander DA. Pharmacology of neuromuscular blocking agents and their reversal. Anesthesiol Clin. 2021;39(3):441-456.

    5. Indexed at, Google Scholar, Crossref

  5. Joseph WG, Richard AJA, Daniel MA. Local Anesthetic Systemic Toxicity: Review of Clinical Pharmacology, Diagnosis, and Management. Curr Rev Clin Anesthesiol. 2020;41(2):99-106.

    6. Indexed at, Google Scholar, Crossref

  6. Jianan L, Yu L, Weiming W. Dexmedetomidine in anesthetic practice: a review of current evidence and future perspectives. Eur J Pharmacol. 2021;911:174542.

    7. Indexed at, Google Scholar, Crossref

  7. Ryan SDG, Amanda ES, Andrew DS. Pharmacogenomics in Perioperative Medicine: A Review of Clinical Applications. Anesthesiol Clin. 2021;39(3):457-471.

    8. Indexed at, Google Scholar, Crossref

  8. Adam JG, Jennifer SG, Mark LG. Ketamine: A Review of Its Pharmacology, Clinical Uses, and Potential Side Effects. Curr Pain Headache Rep. 2020;24(1):6.

    9. Indexed at, Google Scholar, Crossref

  9. Yu-Fang L, Shu-Qi W, Wen-Fei G. Anesthetic-induced cognitive dysfunction: current understanding and future directions. J Anesth. 2022;36(1):111-120.

    10. Indexed at, Google Scholar, Crossref

  10. John SN, John GP, Adam BL. Remimazolam: A New Ultrashort-Acting Benzodiazepine for Anesthesia and Sedation. Anesthesiology. 2021;134(1):110-125.

    11. Indexed at, Google Scholar, Crossref

Get the App